BioSpace News Archive

Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Applications for BRAFTOVI® + MEKTOVI® for patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g.

Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, and Freeline Therapeutics have entered into an exclusive patent and know-how license agreement.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 124,300 shares, and restricted stock units covering an aggregate of 40,350 shares, of BioCryst common stock.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Tuesday, May 2, 2023 at 8:30 a.m. ET.

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that members of the Zimmer Bioment management team will be presenting at the Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 10:15 a.m. Eastern Time.

Mosaic Therapeutics, Ltd, an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients, announced the close of its $28 million series A funding round.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy.

Recently, 6 of Viva’s portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.